Søgeresultater - Shebl, Amgad

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study

    Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study af Wallenhorst, Christopher, Patel, Ami, Shebl, Amgad, Hubsch, Alphonse, Simon, Toby L., Martinez, Carlos

    Udgivet 2020
    Få fuldtekst Få fuldtekst Få fuldtekst
    Text
    Føj til favoritter
    Saved in:
  2. 2
    Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US

    Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US af Martinez, Carlos, Watson, Douglas J., Shebl, Amgad, Wallenhorst, Christopher, Hubsch, Alphonse, Simon, Toby L.

    Udgivet 2017
    Få fuldtekst Få fuldtekst Få fuldtekst
    Text
    Føj til favoritter
    Saved in:
  3. 3
    Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports

    Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis... af Shebl, Amgad, Gabriel, Susie, Van Dinther, Kristy, Hubsch, Alphonse, Lawo, John‐Philip, Hoefferer, Liane, Welsh, Susan

    Udgivet 2020
    Få fuldtekst Få fuldtekst Få fuldtekst
    Text
    Føj til favoritter
    Saved in:
  4. 4
    Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme

    Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme af Greulich, Timm, Chlumsky, Jan, Wencker, Marion, Vit, Oliver, Fries, Michael, Chung, Thomas, Shebl, Amgad, Vogelmeier, Claus, Chapman, Kenneth R., McElvaney, Noel G.

    Udgivet 2018
    Få fuldtekst Få fuldtekst Få fuldtekst
    Text
    Føj til favoritter
    Saved in:
  5. 5
    Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

    Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA stu... af Léger, Jean-Marc, De Bleecker, Jan L, Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Mielke, Orell, Tackenberg, Björn, Shebl, Amgad, Bauhofer, Artur, Zenker, Othmar, Merkies, Ingemar S J

    Udgivet 2013
    Få fuldtekst Få fuldtekst Få fuldtekst
    Text
    Føj til favoritter
    Saved in:
  6. 6
    Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study

    Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneur... af Mielke, Orell, Bril, Vera, Cornblath, David R., Lawo, John‐Philip, van Geloven, Nan, Hartung, Hans‐Peter, Lewis, Richard A., Merkies, Ingemar S.J., Sobue, Gen, Durn, Billie, Shebl, Amgad, van Schaik, Ivo N.

    Udgivet 2019
    Få fuldtekst Få fuldtekst Få fuldtekst
    Text
    Føj til favoritter
    Saved in:

Søgeredskaber: